XRP's price recovered above $1.50 following a shareholder vote approving Evernorth's merger with Armada Acquisition Corp. II, which advances the Ripple-backed company's plan to list on Nasdaq under the ticker XRPN. The merger approval is a key step toward closing the transaction, with Evernorth expected to hold at least 473.3 million XRP at closing. A separate $30 million financing agreement is also tied to the deal's completion. XRP traded around $1.51, reflecting market optimism as the merger vote passed, signaling progress for Evernorth's public market debut and its treasury strategies involving XRP.
XRP price movement is the subject, with Pluang market data providing broader context. Of 50 major cryptocurrencies priced on Pluang, 18 rose and 31 fell today. Kusama (KSM) gained 8.02% to Rp90.626, Aave (AAVE) dropped 4.39% to Rp2.836.909 with a 45% sell order activity, and PancakeSwap (CAKE) rose 4.19% to Rp47.209 as of Oct 01, 2026 02:12 WIB.
Circle has introduced three developer kits for its Arc blockchain that enable apps to embed USDC and EURC stablecoin purchases, lending via the Morpho protocol, and Bitcoin-backed loans using cirBTC collateral without needing to write smart contracts...
Cardinal Health reported robust fiscal year 2026 results, including 14% revenue growth, a 20% increase in gross margin, and doubled free cash flow. Despite challenges like thin margins and higher current liabilities, the company remains strong with F...
At OpenAI's Dev Day, CEO Sam Altman introduced the Decisions API, a tool that allows AI models to quickly choose from predefined options, enhancing speed and reducing costs. This API is similar to TypeSafe AI's Jev, which is designed for fast, effici...
LayerZero has strengthened its role in regulated stablecoins through new institutional partnerships, including Anchorage Digital for Tether’s USAT stablecoin and BDACS for a Korean won-backed stablecoin. These integrations expand LayerZero’s infrastr...
Liquidia Corporation's main product, YUTREPIA, is showing promising growth and generating significant cash flow since its approval in May 2025. This success provides a solid operating foundation for the company's future expansion in pulmonary hyperte...
